Semaglutide Side Effects and Considerations

Introduction to Semaglutide Side Effects

The American Diabetes Association and other guideline societies recommend monitoring for insomnia as a side effect of GLP-1 receptor agonists, including semaglutide, due to its documentation in clinical guidelines 1
The American Gastroenterological Association notes that insomnia is listed among the common side effects that patients may experience while taking semaglutide, as per FDA-approved drug information 1
The risk of insomnia with semaglutide appears to be similar to that seen with other medications in the GLP-1 receptor agonist class, according to the American Gastroenterological Association 2, 3

The American Gastroenterological Association suggests that gradual dose titration of semaglutide may help mitigate side effects, including potential sleep disturbances 2
The American Gastroenterological Association recommends monitoring sleep disturbances, especially during the initial titration phase of the medication 4
If insomnia persists and significantly affects quality of life, dose adjustment or alternative medication options may need to be considered, as advised by the American Gastroenterological Association 2

The American Gastroenterological Association reports that the most frequently reported adverse effects of semaglutide are gastrointestinal, including nausea, vomiting, diarrhea, constipation, and esophageal reflux 2, 5
These gastrointestinal effects are typically dose-dependent and may be more pronounced during initial treatment or dose escalation, according to the American Gastroenterological Association 2, 4
The American Gastroenterological Association recommends gradual dose titration to minimize gastrointestinal side effects 2
The American Gastroenterological Association notes an increased risk of gallbladder disease, including cholelithiasis and cholecystitis, with semaglutide 2, 3
The American Gastroenterological Association reports a risk of pancreatitis with semaglutide, though causality has not been definitively established 2, 5
The American Gastroenterological Association advises monitoring for potential acute kidney injury, particularly in patients with pre-existing kidney disease 5
The American Gastroenterological Association notes a potential for delayed gastric emptying with semaglutide, which may affect absorption of other medications 4, 5

Clinical trials have shown a 38% higher risk of serious adverse events with semaglutide compared to placebo, according to the American Gastroenterological Association 2, 3
Specific serious adverse events reported with semaglutide include pancreatitis, cholelithiasis and cholecystitis, acute myocardial infarction, and gastroenteritis, as noted by the American Gastroenterological Association 2, 3, 4
The American Gastroenterological Association advises that semaglutide is contraindicated in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 2, 4
The American Diabetes Association recommends monitoring patients with diabetes for hypoglycemia, especially if taking other glucose-lowering medications, when using semaglutide 6